In this capacity Ms Baird will provide leadership and strategic direction in the areas of regulatory and quality affairs and in clinical operations.
Most recently, Ms Baird was senior vice president of regulatory, quality and clinical operations with CombinatoRx in Cambridge, Massachddets. Previous to that appointment, Ms Baird held executive management positions for regulatory affairs and quality at Dyax, Curis and CytoTherapeutics.
Ms Baird has earned her PhD in microbiology and immunology from Virginia Commonwealth University in Richmond, Virginia.
Jonathan Gelles, chairman of board of directors, said: “We are truly delighted to attract someone of Lynn’s caliber, capability and expertise. There is no doubt that she will play a significant role in our future growth and success as we advance multiple vaccine products through clinical development.”